Tim Smith

New data indicates that biologic treatments for psoriasis patients were found not to be significantly affected by comorbidities in older patients, widening the understanding of biologic use in different subgroups.

New research shows that mental health, life quality, and symptoms of eczema may all be improved through self-compassion and online mindfulness training that is both scalable and accessible to many.

New data indicates an association between cardiovascular risk factors and psoriasis disease activity, shedding light on potential ways to identify and help those at risk for future heart issues.

New research shows that fall death rates for adults over 65 increased in both rate and number since 1999, indicating the necessity of more work toward fall prevention and reducing fall-related mortality.

A research letter highlighted coverage in The New York Times of a small study on oral minoxidil and this story’s connection with an immediate increase in the drug’s prescription rates.

New data suggests that anti-IL-17A biologics including ixekizumab showed strong self-reported results in signs and symptoms for psoriasis patients.

New data on using narrowband-UVB therapy for chronic plaque psoriasis found that the body’s lower limbs were the most difficult to treat, though excellent responses were still reported.

After spesolimab was found to be useful against generalized pustular psoriasis, this new analysis showed promising results for the treatment despite differences in demographics and other characteristics.

New data indicates a connection between post-surgery cognitive declines and delirium, though future research may be needed to understand the causal pathway.

The announcement resulted from the FDA’s request for manufacturing, administration, and patient monitoring information.

New data indicate that once-daily roflumilast foam in treating seborrheic dermatitis may improve the lives of those in the 5% or more of the global population with the skin disease.

Investigators found that dermatologist and convolutional neural network-cooperation led to improved lesion classification, indicating potential benefits of the human and machine approach for patients.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

In this interview with Bunick, he describes some of the late-breaking research on upbadacitinib he presented at the the Revolutionizing Atopic Dermatitis conference.

In this Q&A interview with Abuabara, she discusses some of the major takeaways from her Revolutionizing Atopic Dermatitis presentation on long-term control of eczema.

New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.

In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.

Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.

In her presentation at the Revolutionizing Atopic Dermatitis conference, Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 nonsteroidal topicals.

In this interview, King discussed his Revolutionizing Atopic Dermatitis presentation on his views about the safety of JAK inhibitors in otherwise healthy eczema patients.

During another interview segment, Silverberg highlighted some new insights into oral JAK-inhibitors from his presentation at the Revolutionizing Atopic Dermatitis conference.

In this interview segment, Silverberg discussed some of the major takeaways from his Revolutionizing Atopic Dermatitis presentation on eligibility for systemic treatments.

Eichenfield discussed the major takeaways from his Revolutionizing Atopic Dermatology conference presentation regarding recent data on PDE4 and JAK inhibitors for eczema patients.

During this interview segment, Singh spoke on the ways in which dermatologists may help infants manage atopic dermatitis, as well as her outlook on the future of treatment.

In this interview, Singh described the major takeaways from her presentation on allergy testing for infants which she gave at the Revolutionizing Atopic Dermatitis conference.

Eichenfield discussed his first presentation at the Revolutionizing Atopic Dermatitis conference, with his discussion covering systemic atopic dermatitis treatment for infants.